eGenesis, a U.S. gene-editing and genome-engineering firm co-founded by Harvard professor Yang Luhan, has secured $125 million in a Series C round of financing to bring the firm’s lead programmes in kidney and islet cell transplant into human proof-of-concept studies.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
